Here, we show that both DL- and NDL-PCBs induce hepatic steatosis, fibrosis, inflammation and HIO by upregulating the expression of hepatic LCN2, resulting in the induction of NAFLD/NASH in vivo and in vitro. The gene discussed is LCN2; the disease is metabolic dysfunction-associated steatotic liver disease.